{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-229770","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-05-19T12:45:19+00:00","discovered_at":"2026-05-19T12:50:00.283874+00:00","generated_at":"2026-05-19T12:50:53.200464+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate","bullets":["60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.","89% of patients showed clinical improvement per investigator global impression at week 12; 79% per patient global impression.","Among 22 patients at 100mg and 300mg BID, no dose discontinuations; 9% had Grade 3+ TRAEs; no rash or stomatitis observed.","Expansion cohorts opened at 400mg QD and 300mg BID for adults/adolescents; pediatric dose-finding ongoing.","All 32 enrolled patients remained on treatment as of April 15, 2026 data cut-off; prior alpelisib/sirolimus use in 72%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-229770","json":"https://secwatch.observer/filing/0001193125-26-229770.json","markdown":"https://secwatch.observer/filing/0001193125-26-229770.md","text":"https://secwatch.observer/filing/0001193125-26-229770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/0001193125-26-229770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/rlay-20260519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-19T12:50:53.200464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}